April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” A specific group of early-stage melanocytes is reduced in vitiligo-affected skin, which may explain treatment resistance.
July 2025 in “Journal of Investigative Dermatology” Machine learning can help identify biomarkers for personalized Pemphigus vulgaris treatment.
IL-18 signaling helps mature Tregs move into the thymus.
2 citations
,
May 2023 in “Cancer medicine” KRT80 may worsen cancer by increasing growth and spread, but its full effects on treatment and outcomes need more research.
127 citations
,
January 2000 in “Journal of Investigative Dermatology” Cytotoxic T cells cause hair loss in chronic alopecia areata.
April 2010 in “Cancer Research” Basal cell carcinomas may use IDO to protect themselves from the immune system.
41 citations
,
July 2016 in “Journal of Investigative Dermatology” Dysplastic nevi have unique gene expressions, making them distinct from common melanocytic nevi.
April 2023 in “Journal of Investigative Dermatology” IL-17 plays a key role in severe hair loss in chronic alopecia areata.
1 citations
,
December 2022 in “Frontiers in Immunology” Tissue environment greatly affects the unique epigenetic makeup of regulatory T cells, which could impact autoimmune disease treatment.
February 2024 in “bioRxiv (Cold Spring Harbor Laboratory)” Activating TLR9 helps heal large wounds and regrow hair by involving a specific type of immune cell.
67 citations
,
December 2009 in “Stem Cells” β-Catenin signaling is involved in brain cell growth after injury and could be a therapy target.
24 citations
,
January 1985 in “Dermatology” Higher levels of certain immune cells in hair follicles may contribute to alopecia areata.
CD28 is a promising target for treating alopecia areata with belatacept.
CD28 is a promising target for treating alopecia areata with belatacept.
45 citations
,
October 2018 in “JCI Insight” Entospletinib effectively prevents eye and skin GVHD in mice.
May 2025 in “Nonlinear Analysis Real World Applications” Reducing CD8+ T cell growth can stabilize alopecia areata.
3 citations
,
November 2005 in “Journal of Investigative Dermatology Symposium Proceedings” Enhancing regulatory T cells may help treat autoimmune diseases like alopecia areata.
32 citations
,
January 2012 in “Clinical & Developmental Immunology” Targeting CD200 could be a new treatment for rheumatoid arthritis.
January 2012 in “Journal of Investigative Dermatology” Some Greek melanoma patients have gene mutations linked to increased cancer risk, a new color feature helps diagnose melanoma, the incidence of a skin condition in the Netherlands is rare, and a gene possibly affects male-pattern baldness.
Keratinocytes can reverse the effects of the GNAQ oncogene, inhibiting melanoma cell growth.
August 2024 in “Cell Death and Disease” Activating TLR9 helps heal wounds and regrow hair by using specific immune cells.
1 citations
,
May 2019 in “Cytotherapy” The new ddPCR method reliably detects unwanted viruses in CAR-T cell products, ensuring their safety for patients.
Deleting the MAD2L1 gene in mice led to rapid tumor growth despite chromosomal instability.
19 citations
,
February 2016 in “Journal of The American Academy of Dermatology” CD3+ T-cell presence is a reliable marker to tell apart alopecia areata from pattern hair loss.
9 citations
,
March 2017 in “Journal of Visualized Experiments” The assay effectively identifies compounds that affect immune cell activation.
November 2025 in “The Journal of Immunology” A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.
77 citations
,
June 2002 in “Journal of Investigative Dermatology” CD44 variant changes start alopecia areata, but don't maintain it.
5 citations
,
February 2008 in “Histopathology” July 2024 in “Journal of Investigative Dermatology” ITK inhibitors may effectively treat alopecia areata.
58 citations
,
September 2019 in “EMBO Molecular Medicine” CDK4/6 inhibitors can protect hair cells from chemotherapy damage.